Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study

Tanya Babich, Pontus Naucler, John Karlsson Valik, Christian G. Giske, Natividad Benito, Ruben Cardona, Alba Rivera, Celine Pulcini, Manal Abdel Fattah, Justine Haquin, Alasdair MacGowan, Sally Grier, Bibiana Chazan, Anna Yanovskay, Ronen Ben Ami, Michal Landes, Lior Nesher, Adi Zaidman-Shimshovitz, Kate McCarthy, David L. PatersonEvelina Tacconelli, Michael Buhl, Susanna Maurer, Jesus Rodriguez-Bano, Isabel Morales, Antonio Oliver, Enrique Ruiz de Gopegui, Angela Cano, Isabel Machuca, Monica Gozalo-Marguello, Luis Martinez-Martinez, Eva M. Gonzalez-Barbera, Iris Gomez Alfaro, Miguel Salavert, Bojana Beovic, Andreja Saje, Manica Mueller-Premru, Leonardo Pagani, Virginie Vitrat, Diamantis Kofteridis, Maria Zacharioudaki, Sofia Maraki, Yulia Weissman, Mical Paul, Yaakov Dickstein, Leonard Leibovici, Dafna Yahav

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


This study aimed to evaluate risk factors for 30-day mortality among hospitalised patients with Pseudomonas aeruginosa bacteraemia, a highly fatal condition. A retrospective study was conducted between 1 January 2009 and 31 October 2015 in 25 centres (9 countries) including 2396 patients. Univariable and multivariable analyses of risk factors were conducted for the entire cohort and for patients surviving ≥48 h. A propensity score for predictors of appropriate empirical therapy was introduced into the analysis. Of the 2396 patients, 636 (26.5%) died within 30 days. Significant predictors (odds ratio and 95% confidence interval) of mortality in the multivariable analysis included patient-related factors: age (1.02, 1.01–1.03); female sex (1.34, 1.03–1.77); bedridden functional capacity (1.99, 1.24–3.21); recent hospitalisation (1.43, 1.07–1.92); concomitant corticosteroids (1.33, 1.02–1.73); and Charlson comorbidity index (1.05, 1.01–1.93). Infection-related factors were multidrug-resistant Pseudomonas (1.52, 1.15–2.1), non-urinary source (2.44, 1.54–3.85) and Sequential Organ Failure Assessment (SOFA) score (1.27, 1.18–1.36). Inappropriate empirical therapy was not associated with increased mortality (0.81, 0.49–1.33). Among 2135 patients surviving ≥48 h, hospital-acquired infection (1.59, 1.21–2.09), baseline endotracheal tube (1.63, 1.13–2.36) and ICU admission (1.53, 1.02–2.28) were additional risk factors. Risk factors for mortality among patients with P. aeruginosa were mostly irreversible. Early appropriate empirical therapy was not associated with reduced mortality. Further research should be conducted to explore subgroups that may not benefit from broad-spectrum antipseudomonal empirical therapy. Efforts should focus on prevention of infection, mainly hospital-acquired infection and multidrug-resistant pseudomonal infection.

Original languageEnglish
Article number105847
JournalInternational Journal of Antimicrobial Agents
Issue number2
StatePublished - Feb 2020
Externally publishedYes

Bibliographical note

Funding Information:
The authors would like to thank the following for their assistance with the manuscript: Alain Lozniewski (Nancy, France); Thibault Mansuy (Nancy, France); Assaf Halavie (Petah Tikva, Israel); and Lia Koren (Petah Tikva, Israel). Funding: None. Competing interests: None. Ethical approval: This study was approved by the Medical Ethical Committees of each participating centre.

Publisher Copyright:
© 2019 Elsevier Ltd


  • Bacteraemia
  • Mortality
  • Pseudomonas
  • Risk factors


Dive into the research topics of 'Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study'. Together they form a unique fingerprint.

Cite this